老年MCL患者常由于各种合并症无法耐受标准免疫化疗。近年来,无化疗的“Chemo-free”方案在老年MCL中的适用性成为研究热点。 近日,有研究结果提示,IR在初诊老年MCL患者中具有优异的疗效,但强烈建议对患者的心血管风险进行基线评价。 >>>5...
Conclusion: In PMLBCL, RCHOP chemotherapy backbone in the frontline therapy is suboptimal but can be used in patients with low IPI. Adapting more intensive chemoimmunotherapy regimens may be considered for patients with high IPI. Salvage chemotherapy has limited activity in patients w...
usedforthestagingandevaluationofthetreatmentresponse.Ithas beenstatedthatinaggressivenon-Hodgkin’slymphoma(NHL),arapid reduction in 18 F-FDG during chemotherapy is associated with a good prognosis [16]. In some reported studies, patients treated with chemo- therapy consisting of cyclophosphamide, doxoru...
compared with 8 cycles of CHOP therapy at initial publica- tion, but their updated data, which have not been published, showed that the survival differences observed between the 2 arms disappeared after long-term follow-up (5). The addition of rituximab to CHOP (R-CHOP) chemo- therapy signi...
Chemoimmunotherapy (CIT), analogous to the treatment of de novo DLBCL, results in low response rates with a median overall survival (OS) of 6–12 months2,3. The combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) remains a frequently used regimen for ...
prednisone] outcomes are worse, as opposed to clinical trials in which there is an inherent selection bias. We tend to select the healthier and less sick patients in trials, so they will probably tolerate better the treatment and they will complete the treatment, and also patients will have le...
在dlbcl中,fγriib表达较弱,由此解释了在其表达和对于利妥昔单抗-chop(r-chop)化疗之间未显示相关性的原因(20,21)。关于激活性fcγr,还发现影响fcγriib活性的多形性,232i等位基因比232t等位基因更有效地抑制bcr介导的钙流(22,23)。然而,weng和levy未能在fl患者中确定这些多形性和对利妥昔单抗治疗的响应...
Dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA.R-EPOCH) is used for upfront treatment of high-risk diffuse large B cell lymphoma (DLBCL). In this study, we compared the outcomes in patients with high-ris
而在国内的研究中,郭晔等[16]对32例复发的DLBCL患者应用R-ICE方案治疗,32例患者均为一线应用6～8个周期R-Chemo方案治疗后达CR,停止治疗后首次复发的患者,经过3个疗程R-ICE方案的挽救治疗,ORR为78.1%,2年PFS率和OS率分别为40.8%和60.7%。可见,对于既往一线治疗中使用过利妥昔单抗的DLBCL复发患者,挽救方案中...
Objective To explore adverse reactions and clinical efficacy of treatment regimen of rituximab monoclonal antibody combined with CHOP regimen(R-CHOP14) for elderly patients with non-Hodgkin' s lymphoma(NHL)and to examine the influence of R-CHOP14 on immune function. Methods With a retrospective stud...